1. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression
- Author
-
Stephen Vida, Marie Saint-Laurent, Pablo Cervantes, Linda Booij, Gabriella Gobbi, Maykel F. Ghabrash, Stefano Comai, Theodore Kolivakis, John Tabaka, Nicolas A. Nuñez, Jessica Di Sante, Nancy Low, Gobbi, Gabriella, Ghabrash, Maykel F., Nuñez, Nicola, Tabaka, John, Di Sante, Jessica, Saint-Laurent, Marie, Vida, Stephen, Kolivakis, Theodore, Low, Nancy, Cervantes, Pablo, Booij, Linda, and Comai, Stefano
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,03 medical and health sciences ,Depressive Disorder, Treatment-Resistant ,Young Adult ,0302 clinical medicine ,Rating scale ,Internal medicine ,augmentation ,medicine ,Humans ,Pharmacology (medical) ,Young adult ,Antipsychotic ,Depression (differential diagnoses) ,Aged ,Retrospective Studies ,Aged, 80 and over ,Psychiatric Status Rating Scales ,antidepressant ,business.industry ,second-generation antipsychotics ,Middle Aged ,second-generation antipsychotic ,medicine.disease ,Personality disorders ,Comorbidity ,Antidepressive Agents ,030227 psychiatry ,Psychiatry and Mental health ,Treatment Outcome ,Psychiatry and Mental Health ,antidepressants ,treatment-resistant depression ,Antidepressant ,Drug Therapy, Combination ,Female ,business ,Treatment-resistant depression ,030217 neurology & neurosurgery ,Antipsychotic Agents - Abstract
Patients with treatment-resistant unipolar depression (TRD) are treated with antidepressant combinations (ADs) or with second-generation antipsychotics plus AD (SGA+AD) augmentation; however, the clinical characteristics, the factors associated independently with response to SGA+AD, and the outcome trajectories have not yet been characterized. We performed a naturalistic study on the latest stable trial (medication unchanged for about 3 months) in 86 TRD patients with resistance to at least two ADs trials, who received ADs (n=36) or SGA+AD (n=50) treatments. Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton-Depression Rating Scale (HAM-D17), and other scales were administered before (T0) and after the latest 3-month stable trial (T3). Compared to ADs, the SGA+AD group showed increased percentage of depression with psychotic features, comorbidity for personality disorders and substance use disorders (SUD), higher number of failed ADs pharmacotherapies and depressive symptoms at T0 on all scales (P
- Published
- 2017